| Ytd | 207.88% | |
| 1y | 312.25% |
| Open | 45.47 | Prev Close | 45.15 | Low | 40.62 | High | 45.59 | Mkt Cap | 5.48B |
| Vol | 2.16M | Avg Vol | 4.53M | EPS | N/A | P/E | N/A | Forward P/E | -24.78 |
| Beta | 2.23 | Short Ratio | 2.29 | Inst. Own | 73.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 14.26 | 200-d Avg | 14.26 | 1yr Est | 60.13 |
DFTX News
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Definium Therapeutics NASDAQ: DFTX said it expects to report top-line results from its Phase III VOY
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX),
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
The average of price targets set by Wall Street analysts indicates a potential upside of 34.9% in De
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biophar
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea
GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervas
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in De
Data highlight the challenges of achieving response and sustained remission in newly diagnosed and e
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”),
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c
Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial opera
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”),
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial re
Definium Therapeutics, Inc. (Nasdaq: DFTX) (the âCompanyâ or âDefiniumâ), a late-stage clini
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”),
DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers r
Top Wall Street analysts changed their outlook on top names. Complete view of changes, incl. upgrade
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”),
Definium Therapeutics (NASDAQ:DFTX) shares climbed about 53% on Monday after the biopharmaceutical c
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regul
Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 poi
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar
Health officials explored restricting specific antidepressants among SSRI drugs-sources
https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex
Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump
https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/
